Abstract 17765: A Meta-analysis of Outcomes at Two and Five Years After the Conclusion of Randomised Controlled Trials of Statin Therapy
Introduction: We examined the long term outcomes for patients in randomised statin trials to investigate if benefits are maintained from on-trial statin therapy
Methods: Using published time to event outcome data for statin and control arm participants with long term observational follow-up, we performed inverse variance meta-analyses of derived hazard ratios at trial end, two years post trial and five years post trial for mortality outcomes, major coronary events and incident cancer.
Results: Long term follow-up data was available for patients for various endpoints from eight statin vs control trials (Table 1). Where reported, similar proportions of patients from each trial arm used statin therapy after trial end. Combined results showed significant reductions in the risk of all-cause mortality, cardiovascular mortality coronary mortality and major coronary events for patients in the statin arm at trial end. For three trials, benefits of prior statin therapy on total mortality five years post trial appeared greater than at study close whereas they remained similar or slightly smaller among the other four trials. In combination the majority of the accrued trial benefits appeared preserved at two years post trial and five years post trial, with the magnitude of risk reduction being only slightly smaller over this time. No effect was observed on the risk of cancer at any timepoint (Table 2).
Conclusions: Participants allocated statin therapy in randomised trials maintained cardiovascular and mortality benefits for at least five years after trial end.
Author Disclosures: J. Fulcher: Honoraria; Modest; Pfizer, Bristol Myers Squibb. R. O'Connell: None. V. Gebski: None. A. Keech: Honoraria; Modest; Astra-Zeneca, Bristol Myers Squibb, Eli Lilly, Pfizer, Sanofi. Honoraria; Significant; Abbott.
- © 2015 by American Heart Association, Inc.